PPARG and Cholestatic liver disease: Another study specifically reported the effects of tectorigenin on cholestatic liver disease, and the results proved that tectorigenin alleviated intrahepatic cholestasis via the activation of peroxisome proliferator-activated receptor gamma (PPARγ) and subsequent NF-κB inhibition and bile salt export pump (BSEP) activation [23].